Clinical trials: Anthrax, open to volunteers
Anthrax
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with systemic anthrax. The study is designed to collect information on safety, clinical benefit (such as extent of anthrax illness and…
- Trial name
- NCT03569514
- Testing
- AIGIV
- Volunteers
- 10 people
- Sponsor
- Emergent BioSolutions
Acute Ischemic Stroke From Large Vessel Occlusion
SGLT2 Inhibitor Utilization Re-perfusion Therapy
Background: Reperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke.
- Trial name
- SUPER (NCT06858436)
- Testing
- Canagliflozin 100mg
- Volunteers
- 150 people
- Sponsor
- Taichung Veterans General Hospital
Inhalational Anthrax
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with inhalational anthrax. This study will be implemented only in the event of a major anthrax exposure event.
- Trial name
- NCT03569553
- Testing
- AIGIV
- Volunteers
- 100 people
- Sponsor
- Emergent BioSolutions
Infections, Bacterial
Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
This observational, open-label, single arm, study is designed such that it may be implemented for any individual with a lab confirmed sporadic case of systemic anthrax disease treated with raxibacumab outside of the current…
- Trial name
- NCT07478471
- Testing
- Collection of samples
- Volunteers
- 10 people
- Sponsor
- Emergent BioSolutions
Anthrax
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent…
- Trial name
- NCT07268612
- Testing
- CYFENDUS
- Volunteers
- 250 people
- Sponsor
- Emergent BioSolutions
Smoking ( Cigarette)
Cigarette Filter Study
The overall purpose of this study is to determine the effects of using charcoal-filtered cigarettes on product perceptions, smoking behaviors, and biomarkers of exposure to tobacco-related toxicants.
- Trial name
- NCT07348679
- Testing
- Charcoal filtered cigarettes with marketing, Charcoal filtered cigarette without marketing, Non-charcoal filtered cigarettes
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Rutgers, The State University of New Jersey
Severe Poisoning With Cardiotropic or Psychotropic Drug, Admission to Intensive Care
Combined Gastrointestinal Decontamination in Acute Severe Poisoning
Gastrointestinal absorption of high dose medication (toxicant) ingested under solid form for suicidal purposes, is prolonged in patients who need intensive care admission and mechanical ventilation.
- Trial name
- DIMREATOX (NCT07201311)
- Testing
- Combination of activated charcoal with polyethylene glycol for digestive decontamination, Standard Treatment (Guideline-Based)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Charcoal, Decontamination, Poisoning
Activated CHARcoal in Poisoned Patient - Pilot Trial
The goal of this clinical pilot trial is to determine the feasibility of the clinical trial. Then the large-scale CHARPP will be conducted in order to determine the efficacity of activated charcoal as a treatment for acute…
- Trial name
- CHARPP-Pilot (NCT05471479)
- Testing
- Activated Charcoal, No activated charcoal
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Laval University
Infections, Bacterial
Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
This field study is designed such that it may be implemented for any individual with symptomatic inhalational anthrax who has been administered raxibacumab for treatment of anthrax following a mass exposure scenario.
- Trial name
- NCT02177721
- Testing
- Sample Collection
- Volunteers
- 100 people
- Sponsor
- Emergent BioSolutions